Clarity Pharmaceuticals Ltd has released a press release.
Final Cohort opens for CL04 Paediatric Neuroblastoma trial
Filed with ASX ·
6ix hasn’t read this filing yet.
Clarity Pharmaceuticals Ltd. on 6ix
Story so far
Earlier from Clarity Pharmaceuticals
- Phase II SABRE prostate cancer trial reaches 50% recruitment
- Positive Guidance from FDA on Phase 3 Prostate Cancer Trial
- Clarity Establishes US Center of Excellence for Research
- Northstar Achieves Key Production Milestones
- COMBAT theranostic prostate cancer trial commences in the US
Later from Clarity Pharmaceuticals
- Clarity Bolsters Antibody Pre-Targeting with IP from MSK
- Theranostic prostate cancer trial advances to cohort 3
- First PC participant treated at the highest dose level
- First neuroblastoma participant treated in highest cohort
- BOP preliminary trial results presented at EANM 2023
Follow Clarity Pharmaceuticals into a list and get an email when it puts out news.
Follow Clarity Pharmaceuticals